Diffuse large B-cell lymphoma - tumour characteristics on RNA and protein level associated with prognosis
Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma subtype. In Sweden 450 new cases are diagnosed annually. With modern anthracycline-containing chemotherapy DLBCL is potentially curable, with an estimated overall cure rate of approximately 50% for patients with advanced stage disease. Through molecular profiling of DLBCL the ?cell-of-origin concept? has been established: patients
